COMP <GO>
BCDA vs ATYR // EV/EBITDA & P/E VALUATION
BioCardia Inc. (NASDAQ) VS. aTyr Pharma Inc. (NASDAQ) • 15-METRIC TALLY: BCDA 1
— ATYR 1
■ METRIC PARITY
LAST: $0.93 (-2.26%) • MKT CAP: $14.0M
valuation
—
LAST: $5.37 (+4.56%) • MKT CAP: $13.5M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BCDA VS. ATYR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BCDA | ATYR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -19.10% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.5 | 97.3 | -59.74 | ATYR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.0M | $13.5M | $526.4K | BCDA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BCDA REV | ATYR REV | BCDA GROSS % | ATYR GROSS % | BCDA FCF | ATYR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $190.0K | — | — | -$7.4M | -$62.1M |
| FY 2024 | $0 | $235.0K | — | — | -$7.9M | -$69.2M |
| FY 2023 | $0 | $353.0K | — | — | -$10.0M | -$33.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BCDA // BETA —
ATYR // BETA —